14 listed companies and 36 queued pharmaceutical companies swarm to Hong Kong stocks.

According to Choice data, as of now, 14 biopharmaceutical and medical device companies have been listed on the Hong Kong Stock Exchange this year, with another 36 related companies waiting in line to go public. The pharmaceutical industry has become a hot track in the Hong Kong stock market, and this trend is expected to continue rising in the second half of this year. Several interviewees mentioned that the pharmaceutical companies currently favored in the market not only have a rich R&D pipeline but also have been validated by a large amount of clinical data. The launch of the "Science Enterprise Line" by the Hong Kong Stock Exchange and the introduction of the 18A chapter listing system have provided support for cutting-edge biopharmaceutical companies to access capital markets, and have solidified Hong Kong's position as a hub for biotechnology financing in Asia.